173 results on '"Canale, Maria Laura"'
Search Results
2. Abstract 15043: Dapagliflozin Reduces Systemic NLRP-3, IL-1 and PCSK9 Levels in Preclinical Models of Short-Term Doxorubicin Cardiotoxicity: New Evidences of SGLT2i Use in Cardioncology
3. Abstract 15045: Anti CTLA-4 and PD-1 Monoclonal Antibodies Increases Systemic SDF-1 and Galectin-3 Levels and Reduces Myocardial Strain Through NLRP3 and MyD-88 Pathways
4. Cardiac Risk Factors for Immunotherapy
5. Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity.
6. Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on ejection fraction reduction, myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.
7. The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients
8. Multidisciplinary Approach in Atrial Fibrillation: As Good as Gold.
9. Addressing Post-Acute COVID-19 Syndrome in Cancer Patients, from Visceral Obesity and Myosteatosis to Systemic Inflammation: Implications in Cardio-Onco-Metabolism.
10. Abstract 12402: Sacubitril-Valsartan Increases Pampk and Reduces Inflammasome, Myddosome, Il-6 and Galectin-3 Levels in Short-Term Doxorubicin-Treated Mice Improving Longitudinal Strain and Ejection Fraction
11. Abstract 12406: Sglt2i Dapagliflozin Associated to Berberine Reduces Cardiac Cell Apoptosis and Necrosis During Exposure to Her-2 Blocking Agents Through Induction of Pampk and Reduction of Inflammasome, Il-6, Methylglyoxal and Leukotrienes-B4 Levels
12. Abstract 10603: Dapagliflozin Increases Ampk, Reduces Fibrosis/Hypertrophy and Nlrp-3, Il-6 and Galectin-3 Levels in Short-Term Doxorubicin-Treated Mice Improving Cardiac Function
13. Atherosclerosis and the Bidirectional Relationship between Cancer and Cardiovascular Disease: From Bench to Bedside—Part 1.
14. Current Data and Future Perspectives on Patients with Atrial Fibrillation and Cancer
15. Corrigendum: Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals
16. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
17. Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy
18. Diagnostic and Prognostic Role of Cardiac Magnetic Resonance Before Implantable Cardioverter Defibrillator
19. Cardio-oncology rehabilitation: are we ready?
20. Italian Association of Hospital Cardiologists Position Paper ‘Gender discrepancy: time to implement gender-based clinical management’
21. Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals
22. Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios
23. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity
24. Cardiac toxicity of chemotherapy for breast cancer: do angiotensin-converting enzyme inhibitors and beta blockers protect?
25. Acute coronary syndromes in cancer patients
26. Report from the Cardio-Oncology Symposium at the Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Annual Congress.
27. Corrigendum: Cardio-oncology in the COVID Era (Co & Co): The never-ending story
28. PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
29. Corrigendum: Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
30. Baseline Troponin Level and Cardiac Toxicity in HER2-positive Early Breast Cancer Patients Receiving Trastuzumab
31. Women at heart: Introducing gender cardio-oncology
32. The puzzling clinical presentation of fluoropyrimidines cardiotoxicity
33. Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways
34. Report from the Cardio-Oncology Symposium at the Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Annual Congress
35. Sacubitril-valsartan improves longitudinal strain and ejection fraction in preclinical models treated with anthracyclines through NLRP3, MyD88 pathways resulting in a reduction of myocardial IL-1β, IL-6, TNF-α and growth factors.
36. Low doses of advanced glycation end-products and fructosilation products promotes premature cell death of human cardiac cells and increases drug resistance of human breast cancer cells exposed to doxorubicin through NLRP3 and MyD88 pathways.
37. Corrigendum: Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story
38. Corrigendum: Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey
39. Case Series: Recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: A Novel Winning Combination in Cardio-Oncology
40. Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story
41. Cardiologic Long-Term Follow-Up of Patients Treated With Chest Radiotherapy: When and How?
42. Prevention of chemotherapy-induced left ventricular dysfunction
43. ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO)
44. Approach to the diagnosis and management of patients with cardiac amyloidosis. A consensus document by the Tuscan section of the Italian Association of Hospital Cardiologists (ANMCO) and the Tusco-Umbrian section of the Italian Society of Cardiology (SIC)
45. Portrait of Italian Cardio-Oncology: Results of a Nationwide Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Survey
46. Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin: A preliminary echocardiographic study
47. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
48. Left Ventricular Rotation and Twist Assessed by Four-Dimensional Speckle Tracking Echocardiography in Healthy Subjects and Pathological Remodeling: a Single Center Experience
49. Diagnosis and early management of heart failure related cancer treatment.
50. Abnormal right ventricular mechanics in early systemic hypertension: a two-dimensional strain imaging study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.